Overweight Clinical Trials in Waterbury, Connecticut

5 studies are recruiting for overweight in Waterbury, Connecticut right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

   This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatmen…

   Stage

   Phase 3

   Ages

   18 to 79

   Site

   ACCOMPLISH-2 Research Site, Waterbury, Connecticut

   Locations

   74 in total

   Run by

   Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

   See if you can join NCT07654374 on ClinicalTrials.gov

2. A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

   The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Chase Medical Research, LLC, Waterbury, Connecticut

   Locations

   187 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07392190 on ClinicalTrials.gov

3. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

   The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Chase Medical Research LLC, Waterbury, Connecticut

   Locations

   87 in total

   Run by

   Amgen

   See if you can join NCT07684235 on ClinicalTrials.gov

4. A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

   The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants w…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Chase Medical Research, LLC, Waterbury, Connecticut

   Locations

   162 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07321886 on ClinicalTrials.gov

5. AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

   This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the tr…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Chase Medical Research LLC, Waterbury, Connecticut

   Locations

   81 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07509307 on ClinicalTrials.gov